首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL2 |
| Uniprot No | P13500 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-99aa |
| 氨基酸序列 | QPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT |
| 预测分子量 | 13.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **文献名称**: "Production and characterization of recombinant human CCL2/MCP-1 for functional studies"
**作者**: Rollins BJ et al.
**摘要**: 研究报道了通过基因工程在哺乳动物细胞中表达重组人CCL2蛋白，并验证其趋化活性，证明其能有效诱导单核细胞迁移，为炎症机制研究提供工具。
2. **文献名称**: "Recombinant CCL2 enhances macrophage-mediated tumor cell phagocytosis in vitro"
**作者**: Qian BZ et al.
**摘要**: 研究利用重组CCL2蛋白探究其在肿瘤微环境中的作用，发现其通过激活巨噬细胞吞噬功能抑制肿瘤生长，为免疫治疗策略提供实验依据。
3. **文献名称**: "Expression and purification of bioactive recombinant murine CCL2 in E. coli"
**作者**: Deshmane SL et al.
**摘要**: 描述利用大肠杆菌系统高效表达重组小鼠CCL2蛋白，通过优化纯化条件获得高活性产物，并证实其在动物模型中促进单核细胞浸润的能力。
4. **文献名称**: "CCL2-dependent synaptic pruning by microglia exacerbates neuropathic pain"
**作者**: Zhang J et al.
**摘要**: 研究通过注射重组CCL2蛋白，揭示其通过激活小胶质细胞介导的突触修剪加重神经病理性疼痛，为靶向CCL2的镇痛治疗提供理论支持。
CCL2 (C-C motif chemokine ligand 2), also known as monocyte chemoattractant protein-1 (MCP-1), is a small secretory cytokine belonging to the CC chemokine family. It plays a critical role in mediating inflammatory responses by recruiting monocytes, memory T cells, and dendritic cells to sites of tissue injury or infection. CCL2 exerts its biological effects through binding to its cognate receptor CCR2. activating downstream signaling pathways involved in cell migration, immune regulation, and angiogenesis.
Recombinant CCL2 protein is engineered using genetic engineering techniques, typically expressed in prokaryotic (e.g., E. coli) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. The purified protein usually retains the native structure and bioactivity, enabling researchers to study its functions in vitro and in vivo. Its molecular weight ranges between 8-15 kDa, depending on expression systems and modifications.
In research, recombinant CCL2 is widely used to investigate mechanisms underlying chronic inflammation, autoimmune diseases, cancer metastasis, and cardiovascular disorders. Elevated CCL2 levels are associated with pathological conditions such as rheumatoid arthritis, atherosclerosis, and tumor microenvironment remodeling. Pharmaceutical studies also target the CCL2/CCR2 axis for therapeutic intervention, including the development of neutralizing antibodies or receptor antagonists.
Quality control of recombinant CCL2 involves analyses like SDS-PAGE, Western blot, and functional assays (e.g., chemotaxis tests) to confirm purity, specificity, and biological activity. Its applications span cell culture studies, animal disease models, and drug screening platforms, making it a vital tool for both basic research and translational medicine.
×
